Tirofiban
- Generic Name
- Tirofiban
- Brand Names
- Aggrastat
- Drug Type
- Small Molecule
- Chemical Formula
- C22H36N2O5S
- CAS Number
- 144494-65-5
- Unique Ingredient Identifier
- GGX234SI5H
- Background
Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.
- Indication
For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy.
- Associated Conditions
- Cardiovascular Events
Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction
- Conditions
- Branch Atheromatous Disease
- Interventions
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 970
- Registration Number
- NCT05310968
- Locations
- 🇨🇳
Mengzhou People's Hospital, Henan, Henan, China
🇨🇳The People's Hospital of Xiuwu County, Jiaozuo, Henan, China
🇨🇳The First People's Hospital of Nanyang, Nanyang, Henan, China
ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion
- Conditions
- Acute Ischemic Stroke
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-03-07
- Target Recruit Count
- 240
- Registration Number
- NCT05225961
- Locations
- 🇪🇸
Virgen del Rocío Hospital, Seville, Spain
🇪🇸Ramón y Cajal Hospital, Madrid, Spain
🇪🇸Complejo Hospital Universitario de Badajoz, Badajoz, Spain
A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke
- Conditions
- Acute Ischemic Stroke
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- GrandPharma (China) Co., Ltd.
- Target Recruit Count
- 266
- Registration Number
- NCT05188417
- Locations
- 🇨🇳
23rd Floor, City Square, No.160 Qiaokou Road, Qiaokou District, Wuhan, Hubei, China
Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke
- Conditions
- Acute Ischemic StrokeIschemic Stroke
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- University of Iowa
- Registration Number
- NCT04818944
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 420
- Registration Number
- NCT04491695
- Locations
- 🇨🇳
Beijing Luhe Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
🇨🇳First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19
- Conditions
- Respiratory FailureEmbolism and ThrombosisPneumonia, ViralCorona Virus Infection
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- University of Milan
- Target Recruit Count
- 5
- Registration Number
- NCT04368377
- Locations
- 🇮🇹
L. Sacco Hospital, Milano, Lombardia, Italy
Early Initiation of Low Dose Tirofiban for PPCI in STEMI Patients.
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT03797729
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)
- Conditions
- Subarachnoid Hemorrhage, Aneurysmal
- Interventions
- Diagnostic Test: MRIDiagnostic Test: Neurological ExamBehavioral: QuestionnairesDiagnostic Test: Vital SignsOther: Standard of Care Treatment
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- David Hasan
- Target Recruit Count
- 30
- Registration Number
- NCT03691727
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI
- Conditions
- Elective Percutaneous Coronary InterventionST Segment Elevation Myocardial Infarction
- Interventions
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2019-06-07
- Lead Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Target Recruit Count
- 1000
- Registration Number
- NCT03406832
- Locations
- 🇨🇳
Huaihe Hospital of Henan University, Kaifeng, Henan, China
🇨🇳Kaifeng Central Hospital, Kaifeng, Henan, China
🇨🇳The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI
- Conditions
- ST Segment Elevation Myocardial InfarctionPrimary Percutaneous Coronary Intervention
- Interventions
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Target Recruit Count
- 1000
- Registration Number
- NCT03406819
- Locations
- 🇨🇳
The People's Hospital of Jiaozuo, Jiaozuo, Henan, China
🇨🇳The second people's Hospital of Jiyuan, Jiyuan, Henan, China
🇨🇳Huaihe Hospital of Henan University, Kaifeng, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.